

RISK FACTORS OF URINARY TRACT INFECTION IN PATIENTS TREATED WITH ABIRATERONE

Vázquez-Sánchez R, Martínez-Nuñez ME, López-Esteban L, Reques-Sastre B, Onteniente-González A, Molina García T.

Hospital Universitario de Getafe, Madrid, Spain

BACKGROUND

Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer.

One of the most common side effect associated with abiraterone is urinary tract infection (UTI).



PURPOSE

To assess abiraterone-associated UTI prevalence rate in cancer patients and the potential factors that contribute to this adverse effect.

METHODS

Retrospective/observational study (September 2011-September 2014)

Patients on treatment for at least one cycle of abiraterone.

Data recorded:

Age
UTI during abiraterone course
Uropathogen
UTI-treatment

Potential risk factors:

Previous use of antibiotics
Urinary surgery
Urinary catheterization

Categorical variables were compared by Chi-square test. Multivariate analysis was performed on parameters with $p < 0.10$ in univariate models.

1 2
3 4

31 patients were included.

Main duration of treatment: 195.28 days.

	UTI	Uropathogen		Risk factors		
		Pathogen	Non typical pathogen	Surgery	Previous antibiotic	Catheter
number of patients	5	2 Proteus 1 E.coli	2	3	3	5

Variables related to UTI

	OR	IC95%	p
Urinary catheterization	10.67	1.91-59.62	0.007
Urinary surgery	14.67	1.83-117.68	0.011

Multivariate analysis: none of the factors were significantly associated with UTI.

RESULTS

- There are patients treated with abiraterone that suffer UTI, but it is necessary to consider other possible risk factor before thinking in a direct side effect.

- There was a trend towards a higher risk of UTI in patients with previous urologic surgery.

CONCLUSIONS

Conflict of interest: Nothing to disclose

Email: rocio.vazquez@salud.madrid.org